Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results
~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ ... | March 30, 2023
Source: marketscreener.com